In-Stent Restenosis

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Biomedical Engineering

Background:

• In-stent restenosis (ISR) is a significant complication following percutaneous coronary intervention (PCI), persisting despite advancements like drug-eluting stents.
• Neoatherosclerosis, a key pathological feature of ISR, demonstrates accelerated progression in drug-eluting stents compared to bare-metal stents.
• Current treatment strategies for ISR remain suboptimal, necessitating further research and improved therapeutic approaches.

Purpose of the Study:

• To review the current understanding of in-stent restenosis (ISR) pathology, diagnosis, and treatment.
• To highlight the role of neoatherosclerosis in ISR development and progression.
• To discuss diagnostic modalities and therapeutic options for managing ISR.

Main Methods:

• Review of current literature on in-stent restenosis, neoatherosclerosis, and interventional cardiology treatments.
• Analysis of diagnostic techniques including coronary angiography and computed tomography angiography.
• Evaluation of treatment strategies such as drug-coated balloons and stent reimplantation.

Main Results:

• Neoatherosclerosis is a critical factor in ISR, particularly accelerated in drug-eluting stents.
• Coronary angiography remains the gold standard for ISR morphology assessment, with computed tomography angiography as a promising noninvasive alternative.
• Optimal treatment selection for ISR requires careful consideration of patient clinical background and lesion morphology.

Conclusions:

• ISR remains a clinical challenge, with neoatherosclerosis being a major contributor.
• Accurate diagnosis through angiography or CT angiography is crucial for guiding treatment decisions.
• Personalized treatment strategies, including drug-coated balloons and stent reimplantation, are essential for managing ISR effectively.